Clinical Trial Goal
To find out:
- The highest dose of MCD024 that's safe to give
- If MCD024 is safe and works well to treat blood cancer that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have one of the following that has relapsed or is refractory:
- Acute myeloid leukemia (AML)
- B-cell acute lymphocytic leukemia (ALL)
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Chronic myelogenous leukemia (CML)
- Hairy cell leukemia (HCL)
- Hodgkin lymphoma
- Myelodysplastic syndrome (MDS)
- Have disease/cancer cells with mutation/marker CD123. Your doctor can tell you this
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with a drug that targets CD123. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
MGD024 is a bispecific T cell engager (BiTE) antibody that targets CD123 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- MGD024 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 1 year. You'll have biopsies and/or scans to see how well the treatment is working.
The Food and Drug Administration (FDA) has not yet approved MGD024.
Locations
Sponsors
lead: MacroGenics
